RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication

A key feature of the pathogenesis of human immunodeficiency virus type 1 (HIV-1) infection is the gradual loss of CD4-positive T cells. A number of gene therapy strategies have been designed with the intent of inhibiting HIV replication in mature T cells. As T cells are products of hematolymphoid differentiation, insertion of antiviral genes into hematopoietic stem cells could serve as a vehicle to confer long-term protection in progeny T cells derived from transduced stem cells. One such "cellular immunization" strategy utilizes the gene coding for the HIV-1 rev trans-dominant mutant protein RevM10 which has been demonstrated to inhibit HIV-1 replication in T-cell lines and in primary T cells. In this study, we used a Moloney murine leukemia virus-based retrovirus encoding a bicistronic message coexpressing RevM10 and the murine CD8-alpha' chain (Lyt2). This vector allows rapid selection of transgene-expressing cells as well as quantitation of transgene expression. We demonstrate that RevM10-transduced CD34-enriched hematopoietic progenitor-stem cells (HPSC) isolated from human umbilical cord blood or from granulocyte colony-stimulating factor-mobilized peripheral blood can give rise to mature thymocytes in the SCID-hu thymus/liver mouse model. The phenotypic distribution of HPSC-derived thymocytes is normal, and expression of the transgene can be detected by flow cytometric analysis. Moreover, we demonstrate that RevM10 can inhibit HIV replication in T cells derived from transduced HPSC after expansion in vitro. This is the first demonstration of anti-HIV efficacy in T cells derived from transduced human HPSC.

[1]  I. Plavec,et al.  Sustained retroviral gene marking and expression in lymphoid and myeloid cells derived from transduced hematopoietic progenitor cells. , 1996, Gene therapy.

[2]  G. Dranoff,et al.  A cell surface marker gene transferred with a retroviral vector into CD34+ cord blood cells is expressed by their T-cell progeny in the SCID-hu thymus. , 1996, Blood.

[3]  G. Nabel,et al.  Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[4]  I. Plavec,et al.  A novel human amphotropic packaging cell line: high titer, complement resistance, and improved safety. , 1996, Virology.

[5]  D. Kohn,et al.  Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune-deficient mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Thomas O. Toole,et al.  Hematopoietic potential of cryopreserved and ex vivo manipulated umbilical cord blood progenitor cells evaluated in vitro and in vivo. , 1996, Blood.

[7]  T. Reynolds,et al.  T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients , 1996, Nature Medicine.

[8]  C. Eaves,et al.  Rapid and efficient selection of human hematopoietic cells expressing murine heat-stable antigen as an indicator of retroviral-mediated gene transfer. , 1996, Blood.

[9]  I. Plavec,et al.  Detection of intracellular HIV-1 Rev protein by flow cytometry. , 1995, Journal of immunological methods.

[10]  S. Karlsson,et al.  Selection of transduced CD34+ progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[11]  E. Böhnlein,et al.  Retroviral end-point titer is not predictive of gene transfer efficiency: implications for vector production. , 1995, Gene therapy.

[12]  M. Daucher,et al.  Analysis of trans-dominant mutants of the HIV type 1 Rev protein for their ability to inhibit Rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics. , 1995, AIDS research and human retroviruses.

[13]  Evelina Mazzolari,et al.  Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA− Immunodeficient Patients , 1995, Science.

[14]  K. Weinberg,et al.  Engraftment of gene–modified umbilical cord blood cells in neonates with adenosine deaminase deficiency , 1995, Nature Medicine.

[15]  É. Oksenhendler,et al.  Infection frequency of dendritic cells and CD4+ T lymphocytes in spleens of human immunodeficiency virus-positive patients , 1995, Journal of virology.

[16]  B. Fox,et al.  Genetic modification of human peripheral blood lymphocytes with a transdominant negative form of Rev: safety and toxicity. , 1995, Human gene therapy.

[17]  A. Bahnson,et al.  Centrifugal enhancement of retroviral mediated gene transfer. , 1995, Journal of virological methods.

[18]  A. Nienhuis,et al.  Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. , 1995, Blood.

[19]  I. Plavec,et al.  RevM10-mediated inhibition of HIV-1 replication in chronically infected T cells. , 1995, Human gene therapy.

[20]  N. Sarver,et al.  Gene therapy and immune restoration for HIV disease , 1995, The Lancet.

[21]  S. Jagannath,et al.  Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin- subpopulation from mobilized peripheral blood. , 1995, Blood.

[22]  D. Kraft,et al.  HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo. , 1995, Immunity.

[23]  D. Kohn,et al.  Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Clark,et al.  Selective thymocyte depletion in neonatal HIV-1 thymic infection , 1993, AIDS.

[25]  A. Fauci,et al.  Multifactorial nature of human immunodeficiency virus disease: implications for therapy. , 1993, Science.

[26]  S. Orkin,et al.  Long-term in vivo expression of a murine adenosine deaminase gene in rhesus monkey hematopoietic cells of multiple lineages after retroviral mediated gene transfer into CD34+ bone marrow cells. , 1993, Blood.

[27]  Irvin S. Y. Chen,et al.  The SCID-hu mouse as a model for HIV-1 infection , 1993, Nature.

[28]  J. McCune,et al.  HIV induces thymus depletion in vivo , 1993, Nature.

[29]  Ashley T. Haase,et al.  Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS , 1993, Nature.

[30]  J. Hauber,et al.  Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Malim,et al.  Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication , 1992, The Journal of experimental medicine.

[32]  M. Roncarolo,et al.  Human hematopoietic cells and thymic epithelial cells induce tolerance via different mechanisms in the SCID-hu mouse thymus , 1992, The Journal of experimental medicine.

[33]  J. McCune,et al.  The SCID-hu mouse: a small animal model for HIV infection and pathogenesis. , 1991, Annual review of immunology.

[34]  J. McCune,et al.  Long-term human hematopoiesis in the SCID-hu mouse , 1990, The Journal of experimental medicine.

[35]  S E Macatonia,et al.  Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. , 1990, Immunology.

[36]  M. Malim,et al.  Functional dissection of the HIV-1 Rev trans-activator—Derivation of a trans-dominant repressor of Rev function , 1989, Cell.

[37]  Y. Cao,et al.  Megakaryocytes of human immunodeficiency virus-infected individuals express viral RNA. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[38]  E. Wimmer,et al.  Initiation of protein synthesis by internal entry of ribosomes into the 5' nontranslated region of encephalomyocarditis virus RNA in vivo , 1989, Journal of virology.

[39]  I. Weissman,et al.  The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. , 1988, Science.

[40]  G. Nolan,et al.  Formal proof that different-size Lyt-2 polypeptides arise from differential splicing and post-transcriptional regulation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Hirsch,et al.  Infection of monocyte/macrophages by human T lymphotropic virus type III. , 1986, The Journal of clinical investigation.

[42]  R. Gallo,et al.  Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Oroszlan,et al.  Isolation from cats of an endogenous type C virus with a novel envelope glycoprotein , 1985, Journal of virology.